56 related articles for article (PubMed ID: 9431830)
1. Metabolism of Benzalkonium Chlorides by Human Hepatic Cytochromes P450.
Seguin RP; Herron JM; Lopez VA; Dempsey JL; Xu L
Chem Res Toxicol; 2019 Dec; 32(12):2466-2478. PubMed ID: 31730751
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism.
Kóbori L; Kõhalmy K; Porrogi P; Sárváry E; Gerlei Z; Fazakas J; Nagy P; Járay J; Monostory K
Br J Clin Pharmacol; 2008 Mar; 65(3):428-36. PubMed ID: 18070218
[TBL] [Abstract][Full Text] [Related]
3. Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s.
Lindmark B; Lundahl A; Kanebratt KP; Andersson TB; Isin EM
Br J Pharmacol; 2018 Jun; 175(11):2116-2129. PubMed ID: 29574682
[TBL] [Abstract][Full Text] [Related]
4. The Utility of Mixed Effects Models in the Evaluation of Complex Genomic Traits In Vitro.
Alade N; Nath A; Isoherranen N; Thummel KE
Drug Metab Dispos; 2023 Nov; 51(11):1455-1462. PubMed ID: 37562955
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
7. Role of active metabolites in the use of opioids.
Coller JK; Christrup LL; Somogyi AA
Eur J Clin Pharmacol; 2009 Feb; 65(2):121-39. PubMed ID: 18958460
[TBL] [Abstract][Full Text] [Related]
8. Candidate gene polymorphisms predicting individual sensitivity to opioids.
Kasai S; Hayashida M; Sora I; Ikeda K
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):269-81. PubMed ID: 17999051
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans.
Schmidt H; Lötsch J
Eur J Clin Pharmacol; 2007 Nov; 63(11):1045-54. PubMed ID: 17786418
[TBL] [Abstract][Full Text] [Related]
10. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis.
Webb JA; Rostami-Hodjegan A; Abdul-Manap R; Hofmann U; Mikus G; Kamali F
Br J Clin Pharmacol; 2001 Jul; 52(1):35-43. PubMed ID: 11453888
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing.
Ammon S; Hofmann U; Griese EU; Gugeler N; Mikus G
Br J Clin Pharmacol; 1999 Sep; 48(3):317-22. PubMed ID: 10510141
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine.
Kirkwood LC; Nation RL; Somogyi AA
Br J Clin Pharmacol; 1997 Dec; 44(6):549-55. PubMed ID: 9431830
[TBL] [Abstract][Full Text] [Related]
13. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
14. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
Hutchinson MR; Menelaou A; Foster DJ; Coller JK; Somogyi AA
Br J Clin Pharmacol; 2004 Mar; 57(3):287-97. PubMed ID: 14998425
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
Wilkinson GR
J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland.
Brosen K
Drug Metab Pers Ther; 2015 Sep; 30(3):147-63. PubMed ID: 25719307
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
